Herpesvirus saimiri-based gene delivery vectors

被引:20
作者
Griffiths, RA
Boyne, JA
Whitehouse, A [1 ]
机构
[1] Univ Leeds, Fac Biol Sci, Inst Mol & Cellular Biol, Leeds LS2 9JT, W Yorkshire, England
[2] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England
基金
英国生物技术与生命科学研究理事会; 英国惠康基金;
关键词
D O I
10.2174/156652306775515529
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Herpesviruses possess a number of characteristics which make them promising gene delivery vectors. These include their capacity to package large amounts of heterologous DNA and an ability to establish persistent, lifelong infections, where the viral genome remains as a circular non-integrated episome. Herpesvirus saimiri (HVS) is the prototype gamma-2 herpesvirus and is currently being developed as a potential gene delivery vector. In addition to the above properties, HVS-based vectors have the ability to infect a wide range of human cell lines and primary cultures with high efficiencies. Moreover, upon infection the vital genome persists as high copy number, circular, non-integrated episomes which segregate to progeny cells upon division. This allows the HVS-based vector to stably transduce a dividing cell population and provide sustained heterologous gene expression. As such, it offers the characteristics of an artificial chromosome combined with a highly efficient delivery system. This review aims to describe the assessment of HVS-based vectors in both in vitro and in vivo studies, highlighting new developments and possible applications for the treatment of genetic diseases.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 138 条
[81]  
Mahmood Kutubuddin, 2005, Genet Vaccines Ther, V3, P1, DOI 10.1186/1479-0556-3-1
[82]   Mapping EBNA-1 domains involved in binding to metaphase chromosomes [J].
Marechal, V ;
Dehee, A ;
Chikhi-Brachet, R ;
Piolot, T ;
Coppey-Moisan, M ;
Nicolas, JC .
JOURNAL OF VIROLOGY, 1999, 73 (05) :4385-4392
[83]   Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial [J].
Markert, JM ;
Medlock, MD ;
Rabkin, SD ;
Gillespie, GY ;
Todo, T ;
Hunter, WD ;
Palmer, CA ;
Feigenbaum, F ;
Tornatore, C ;
Tufaro, F ;
Martuza, RL .
GENE THERAPY, 2000, 7 (10) :867-874
[84]   Replication-competent herpes simplex viral vectors for cancer therapy [J].
Markovitz, NS ;
Roizman, B .
ADVANCES IN VIRUS RESEARCH, VOL 55, 2000, 55 :409-424
[85]   A γ34.5 mutant of herpes simplex 1 causes severe inflammation in the brain [J].
McMenamin, MM ;
Byrnes, AP ;
Charlton, HM ;
Coffin, RS ;
Latchman, DS ;
Wood, MJA .
NEUROSCIENCE, 1998, 83 (04) :1225-1237
[86]   Potential and limitations of a γ34.5 mutant of herpes simplex 1 as a gene therapy vector in the CNS [J].
McMenamin, MM ;
Byrnes, AP ;
Pike, FG ;
Charlton, HM ;
Coffin, RS ;
Latchman, DS ;
Wood, MJA .
GENE THERAPY, 1998, 5 (05) :594-604
[87]   Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome [J].
Messerle, M ;
Crnkovic, I ;
Hammerschmidt, W ;
Ziegler, H ;
Koszinowski, UH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14759-14763
[88]   ATTENUATED MULTI-MUTATED HERPES-SIMPLEX VIRUS-1 FOR THE TREATMENT OF MALIGNANT GLIOMAS [J].
MINETA, T ;
RABKIN, SD ;
YAZAKI, T ;
HUNTER, WD ;
MARTUZA, RL .
NATURE MEDICINE, 1995, 1 (09) :938-943
[89]   Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: Determinants of its pathogenicity? [J].
Neipel, F ;
Albrecht, JC ;
Fleckenstein, B .
JOURNAL OF VIROLOGY, 1997, 71 (06) :4187-4192
[90]   Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS [J].
Olschowka, JA ;
Bowers, WJ ;
Hurley, SD ;
Mastrangelo, MA ;
Federoff, HJ .
MOLECULAR THERAPY, 2003, 7 (02) :218-227